Drug Trial Radar · NCT01358578
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
Last checked: Nov 20, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,306
Actual
Start
Jun 2011
Primary completion
Jul 2013
Study completion Jul 2013
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
Conditions
- Chronic Plaque Psoriasis
Interventions
PlaceboDrug
Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept
secukinumab (AIN457)Drug
secukinumab (AIN457) 150mg or 300mg subcutaneous
etanerceptDrug
etanercept 50mg subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) .Time frame: 12 wks
- Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure:IGA (Investigator's Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12Time frame: 12 wks
Locations
152 sites in 23 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
High Point, North Carolina
Novartis Investigative Site
Warren, Ohio
Novartis Investigative Site
Portland, Oregon
Novartis Investigative Site
Johnston, Rhode Island
Novartis Investigative Site
Charleston, South Carolina
Novartis Investigative Site
Kingsport, Tennessee
Novartis Investigative Site
San Antonio, Texas
Novartis Investigative Site
Norfolk, Virginia
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Mendoza, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires F.D., Argentina
Novartis Investigative Site
Kogarah, New South Wales, Australia
Novartis Investigative Site
Woolloongabba, Queensland, Australia
Novartis Investigative Site
Carlton, Victoria, Australia
Novartis Investigative Site
East Melbourne, Victoria, Australia
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Edmonton, Alberta, Canada
Novartis Investigative Site
Surrey, British Columbia, Canada
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Halifax, Nova Scotia, Canada
Novartis Investigative Site
Markham, Ontario, Canada
Novartis Investigative Site
Richmond Hil, Ontario, Canada
Novartis Investigative Site
Waterloo, Ontario, Canada
Novartis Investigative Site
Sainte-Foy, Quebec, Canada
Novartis Investigative Site
Barranquilla, Colombia
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Bucaramanga, Colombia
Novartis Investigative Site
Alexandria, Egypt
Showing 40 of 152 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.